Cita APA (7a ed.)
Cheng, Y., Liu, L., Xue, Y., Zhou, S., & Li, Y. (2022). An open‐label, phase 1, randomized, three treatments, three‐period, crossover, relative bioavailability study of CC‐292, a potent and orally available inhibitor of bruton tyrosine kinase. Journal of Clinical Pharmacy & Therapeutics, 47(8), 1186-1194.
Cita Chicago Style (17a ed.)
Cheng, Yiming, Liangang Liu, Yongjun Xue, Simon Zhou, y Yan Li. "An Open‐label, Phase 1, Randomized, Three Treatments, Three‐period, Crossover, Relative Bioavailability Study of CC‐292, a Potent and Orally Available Inhibitor of Bruton Tyrosine Kinase." Journal of Clinical Pharmacy & Therapeutics 47, no. 8 (2022): 1186-1194.
Cita MLA (9a ed.)
Cheng, Yiming, et al. "An Open‐label, Phase 1, Randomized, Three Treatments, Three‐period, Crossover, Relative Bioavailability Study of CC‐292, a Potent and Orally Available Inhibitor of Bruton Tyrosine Kinase." Journal of Clinical Pharmacy & Therapeutics, vol. 47, no. 8, 2022, pp. 1186-1194.
Precaución: Estas citas no son 100% exactas.